Skip to main content

Lithium Linked to Risk for Thyroid Dysfunction, CKD in Bipolar Disorder

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 12, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 12, 2025 -- Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with incident bipolar disorder (BD), according to a study published online Feb. 11 in JAMA Network Open.

Joe Kwun Nam Chan, Ph.D., from the University of Hong Kong, and colleagues examined the risk for thyroid and kidney dysfunction in patients aged 15 years or older with incident BD treated with lithium and other mood stabilizers and antipsychotics in an Asian population in Hong Kong.

Overall, 4,752, 4,500, and 7,029 individuals had analyzable data for hypothyroidism, hyperthyroidism, and CKD, respectively. The researchers found that compared with nonlithium treatments, lithium was associated with an increased risk for hypothyroidism and CKD3+ (adjusted hazard ratios, 2.00 and 1.35, respectively), but not with CKD4+ or end-stage kidney disease. Elevated rates of hypothyroidism, hyperthyroidism, and CKD3+ were seen in association with higher lithium serum levels (adjusted hazard ratios, 2.08, 1.81, and 2.11, respectively). There was an association seen for a greater number of lithium toxicity episodes with increased CKD3+ risk. Compared with lithium, valproate, olanzapine, quetiapine, and risperidone generally exhibited a lower likelihood of thyroid dysfunction and CKD3+, with no difference in advanced CKD. Mean lithium serum levels >0.5028, >0.5034, and >0.5865 mEq/L represented thresholds associated with hypothyroidism, hyperthyroidism, and CKD3+, respectively.

"Our findings further identified thresholds of lithium serum levels associated with thyroid and kidney abnormalities, thereby providing empirical evidence to inform clinical guidelines on recommending lithium treatment that balances the efficacy and safety," the authors write.

Several authors disclosed ties to the pharmaceutical and medical technology industries.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Obinutuzumab Efficacious for Renal Response in Lupus Nephritis

WEDNESDAY, Feb. 26, 2025 -- For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for...

Screen Time Tied to Manic Symptoms in Preteens

MONDAY, Feb. 24, 2025 -- Screen time such as social media and video games may be associated prospectively with manic symptoms in early adolescence, according to a study published...

Body Weight Cycling Tied to Increased Risk for Renal Events in Type 1 Diabetes

MONDAY, Feb. 10, 2025 -- For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an increased risk for renal...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.